Highlights from several solid tumour trials in both early and late stage disease.
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
Commentary on Day 1 of the AACR20 Virtual Meeting
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.
KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib
Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?
On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.
Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
Drugging the undruggable with creative approaches to molecule development
